Cyclopharm Limited
Cyclopharm Limited is an Australia-based radiopharmaceutical company.
The business
Cyclopharm Limited is an Australia-based radiopharmaceutical company. The Company's principal activity is engaged in the manufacture and sale of medical equipment and radiopharmaceuticals, including associated research and development and distribution of third-party products to the diagnostic imaging sector. Its Technegas product is a broad-spectrum diagnostic lung imaging technology for visualization of pulmonary ventilation and lung function. It includes the sale of diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism and other respiratory conditions. The Company uses Technegas technology, which is a structured ultra-fine dispersion of radioactive labelled carbon, produced by using driedTechnetium-99m in a carbon crucible. Company distributes its products in approximately 65 countries.
Small Caps Research
No research on Cyclopharm Limited yet
We cover the ASX small-cap market one company at a time. Request coverage and we’ll prioritise CYC based on demand.
Share price
Market Statistics
Valuation
Trading Activity
Performance
Latest news
Cyclopharm Secures 11-Site US Technegas Deployment with UH Cleveland
Cyclopharm to roll out Technegas at 11 UH Cleveland sites within weeks, expanding US footprint with immediate, recurring revenue from imaging procedures.
Cyclopharm to Install Technegas Platform in University of Pennsylvania Health System Network
Cyclopharm inks multi-site UPHS deal to roll Technegas across 11 locations, starting at UPenn. Major US expansion milestone with recurring revenue potential.
Cyclopharm Secures NIH Approval for Technegas, Boosting US Expansion
Cyclopharm wins NIH approval for Technegas, secures US purchase order; installation under FSS imminent as funding targets 250-300 US installs by H2 2026.
Cyclopharm granted maximum US market patent extension for Technegas imaging kit
Cyclopharm (ASX: CYC) has gained further momentum in its strategy to grow sales of its Technegas kit in the US after being granted an extension to its patent there. The new United States Patent and Trademark Office (USPTO) approval provides for the maximum patent term extension allowable of five years, covering the Technegas kit to […]
Looking for charts & signals? See the tab.
Unlock the full research library - free.
Create a free account to access every broker report, CEO interview, IPO alert, and daily market wrap. No credit card. No paywall.